EDX Medical Group has entered into an agreement with Spire Healthcare Group to advance diagnostic innovations aimed at improving the detection and treatment of major diseases, including cancer, cardiovascular and infectious conditions.

EDX Medical is developing a range of ‘super tests’ for prostate, bowel and testicular cancer. It also provides molecular profiling cancer tests and a platform assessing tumour responses to medicines.

The agreement will explore ways to apply new diagnostic products and patient testing services to Spire Healthcare’s network.

Potential initiatives include promoting clinical products, enhancing patient referral pathways and developing joint healthcare propositions based on improved understanding of patient biology and disease risk.

Professor Sir Chris Evans, founder and chief scientific officer of EDX Medical, said: “Spire Healthcare is an outstanding healthcare leader and we at EDX Medical are delighted to sign this agreement, which paves the way for us to work together to further improve the delivery of innovative diagnostics and class-leading personalised medicine for patients.”

Dr Mike Hudson, CEO of EDX Medical, added: “We are excited to enter this new initiative with Spire Healthcare, which promises to unlock important benefits for Spire’s patients by providing their doctors with early access to advanced clinical diagnostic tools, enabling the delivery of world-class personalised medicine.”

Lumanity and the Parker Institute for Cancer Immunotherapy (PICI) have announced an alliance to accelerate the development and delivery of new cancer immunotherapies.

The partnership brings together PICI’s translational research expertise and network of collaborators with Lumanity’s commercial and development strategy capabilities.

The agreement will see Lumanity provide targeted support to selected PICI-affiliated programmes advancing towards clinical development, company formation or commercialisation.

Areas of collaboration may include indication prioritisation, evidence generation and market access planning.

The alliance is designed to improve development efficiency and support earlier strategic decision-making in a space where scientific advances are often slowed by challenging regulatory, access and reimbursement pathways.

Tarak Mody, Chief Business Officer at PICI, commented: “Together, we’re strengthening the infrastructure that helps therapies reach patients with a clearer value proposition.”

Jeff Bockman, Head of Lumanity’s Oncology Center of Excellence, added: “Our goal is to guide promising science through the decisions that determine whether it ultimately reaches patients.”

The collaboration reflects a shared focus on aligning scientific discovery with practical delivery.

Patient recruitment, regulatory scrutiny and real-world value assessment continue to shape the trajectory of immunotherapy development, making partnerships such as these increasingly important.